Citations

Clear

941 citation(s) found for "Tan, MH".

Beyond Human Limits: The Promise and Pitfalls of Large Language Models in Radiology Research
Reyes, Chloe, Nguyen, Evie, Alexander, Lauren F. , Deahl, Zoe, Khandelwal, Ashish , Mayes, Connor, Alexander, Lauren F , Reyes, Chloe, Bhayana, Rajesh , Mayes, Connor, Zulfiqar, Maria , Tan, Nelly

Mayo Clinic

Journal of Computer Assisted Tomography | April 22, 2025 | Volume: 49 | Issue: 4 | Pages: 545-553

10.1097/rct.0000000000001709 | PMID 40262653 Get It

This review examines the applications and challenges of large language models (LLMs), like OpenAI’s ChatGPT, in radiology research. ChatGPT can assist radiology researchers in generating new ideas, finding and summarizing research papers, designing studies, analyzing data, and facilitating manuscript writing. LLMs are powerful tools with numerous applications in radiology research. However, users should be mindful of potential pitfalls, such as producing incorrect or biased outputs and inconsistent responses, along with ethical and privacy concerns. We discuss approaches to optimize models and address these issues, including prompting techniques like chain-of-thought prompting, retrieval-augmented generation, and fine-tuning. For researchers, prompt engineering can be particularly effective. This review seeks to demonstrate how researchers can utilize ChatGPT for radiology research while offering strategies to mitigate associated risks. We aim to help researchers harness these potent tools to safely boost their productivity.
Abstract 4423: CLL drug resistance- A multifaceted mechanism
Finke, B., Darby, Heather C., McCabe, Chantal E. , O’Brien, Daniel R. , Chen, Yi , Tan, Fenlai , Anthony, Stephen P. , Chen, Yu , Sinha, Sutapa , Han, Weiguo , Wang, Zhiquan , Finke, Brianna M., Rabe, Kari G. , Slager, Susan L. , Parikh, Sameer A. , Braggio, Esteban , Dai, Bing, Shen, Yue, Kay, Neil E.

Mayo Clinic

Cancer Research | April 21, 2025 | Volume: 85 | Issue: 8_Supplement_1 | Pages: 4423-4423

10.1158/1538-7445.am2025-4423 Get It

Abstract Despite the advent of novel targeted therapies with high overall response rates, chronic lymphocytic leukemia (CLL) is still largely incurable due to the development of resistance. The bone marrow microenvironment (BMME) plays an important role in the survival and drug resistance in CLL. BM stromal cells (BMSCs) are considered a key component of BMME. Our long-term goal is to gain further insights of BMSCs-CLL crosstalk influencing both survival and drug resistance in CLL. To understand the global biologic changes that occur in leukemic CLL cells when in contact with BMSCs, we assessed RNA-seq in paired CLL cells isolated from untreated blood and BM and in untreated patients’ CLL cells cultured alone or with BMSCs. CLL cells from blood/BM and cultured alone/with BMSCs were also examined by Immunoprecipitation (IP), Western blot (WB), untargeted metabolomics (LCMS+GCMS), and preclinical drug sensitivity assays. We detected only 13 upregulated genes that overlap between CLL cells from BM and cocultured with BMSCs (p&lt0.05, fold change &gt1.5). When we analyzed the expression of these 13 genes in CLL cells from a cohort of 162 untreated patients by RNA-seq, we found associations between 4 genes (PNP, C16orf54, MOB3A, CDK2AP2) and clinical outcomes including overall survival (OS), progression free survival (PFS), and time to first treatment (TTFT) [multivariable Cox proportional hazards models, p&lt0.05]. Of the 4 genes, purine nucleoside phosphorylase (PNP), an enzyme in the purine pathway, had the most significant association with OS, PFS, and TTFT. Metabolomic profiling indicated an increased level of purine pathway metabolites adenosine, adenine, inosine, and hypoxanthine in cocultured CLL cells. WB analysis showed variable baseline PNP protein expression with 2 cohorts: low /no (L) and high (H) PNP using CLL blood cells. An induction in PNP protein levels were noticed in CLL cells expressing only LPNP when cocultured. Given the association of HPNP with adverse clinical outcomes, we tested for L vs. HPNP cohorts drug sensitivity to known BTK inhibitors(is) or Bcl2is. Treatment of CLL cells from untreated patients with Bcl2is venetoclax, S55746, and LP-118 (Bcl2-Bclxli, Newave) showed increased sensitivity to the Bcl2/Bclxlis in HPNP but not in LPNP cells. In addition, BTKis showed no difference in drug sensitivity associated with CLL PNP levels. To explain this discrepancy, WB and IP analyses were conducted in L vs. HPNP leukemic cells for apoptotic profiles, where we found increased phosphorylated-Bcl2(S70) and an increased association of Bcl2 with Bax in LPNP-expressing CLL cells compared to HPNP. These findings support increased resistance to apoptosis afforded by inhibiting Bcl2 for LPNP vs. HPNP-expressing CLL cells. Our future goals are to continue to understand the prognostic significance of the 4 genes with adverse clinical outcomes and to investigate how best to exploit the peculiar, enhanced sensitivity to Bcl2/Bclxlis found in the HPNP CLL cells. Citation Format: Sutapa Sinha, Weiguo Han, Zhiquan Wang, Brianna M. Finke, Heather C. Darby, Kari G. Rabe, Susan L. Slager, Chantal E. McCabe, Daniel R. O'Brien, Sameer A. Parikh, Esteban Braggio, Yi Chen, Fenlai Tan, Stephen P. Anthony, Yu Chen, Bing Dai, Yue Shen, Neil E. Kay. CLL drug resistance- A multifaceted mechanism [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 4423.
Abstract 5858: Prognostic and predictive role of T cell infiltration in stage III colon cancer (CC) treated with celecoxib: CALGB/SWOG 80702
Twombly, Tyler S., Zhao, Melissa , Shergill, Ardaman , Kumar, Pankaj , Couture, Félix , Kuebler, Philip , Krishnamurthi, Smitha , Shields, Anthony F. , Fuchs, Charles S. , Takashima, Yasutoshi , Ma, Chao , Shi, Qian , Costa, Andressa Dias , Väyrynen, Juha P. , Tan, Benjamin, O’Reilly, Eileen M. , Ogino, Shuji , Meyerhardt, Jeffrey A. , Nowak, Jonathan A.

Mayo Clinic

Cancer Research | April 21, 2025 | Volume: 85 | Issue: 8_Supplement_1 | Pages: 5858-5858

10.1158/1538-7445.am2025-5858 Get It

Observational studies have demonstrated that aspirin and/or PTSG2 inhibitor (e.g., celecoxib) use, before or after colon cancer (CC) diagnosis, is associated with a lower risk of recurrence. However, a randomized trial of adjuvant celecoxib therapy in stage III CC did not show improved survival compared to placebo treatment. We therefore hypothesized that immune microenvironment features may identify patient subgroups with stronger survival benefits from anti-inflammatory celecoxib treatment. Drawing from an NCI-Intergroup trial (Cancer and Leukemia Group B [now Alliance for Clinical Trials in Oncology]/SWOG 80702) for patients with stage III resected CC that compared 3 versus 6 months of adjuvant fluorouracil, leucovorin, and oxaliplatin ± 3 years of celecoxib, we conducted tissue-based tumor microenvironment profiling on 1,098 resected tumors using a custom 9-plex, T-cell multiplex immunofluorescence assay coupled with digital image analysis and supervised machine learning. The Kaplan-Meier method was used to describe disease-free survival, based on T cell density, and log-rank testing was performed. Cox proportional hazards models were used to examine unadjusted and adjusted associations between T cell density and disease-free survival (DFS). Two-sided P values ≤0.05 were considered statistically significant. We found that higher CD3+ T cell density was associated with longer DFS with an adjusted hazard ratio (HR) of 0.69 (95% confidence interval [CI] 0.52-0.91) for patients with densities in the highest tertile as compared the lowest tertile (P=0.01). T cell subset analysis showed that stromal regulatory T helper cells (HR 0.42 comparing highest to lowest tertile, CI 0.31-0.58, P<0.001) and stromal memory cytotoxic T cells (HR 0.55 comparing highest to lowest tertile, CI 0.42-0.74, P<0.001) were most strongly associated with longer DFS. Compared to the placebo group, adjuvant celecoxib use associated with improved DFS for patients with low but not high stromal CD3+ T cell density (adjusted HRs of 0.45 [CI 0.31-0.65] for lowest tertile and 1.13 [CI 0.73-1.74] for highest tertile; Pinteraction=0.01). This association was also seen when the analysis was restricted to microsatellite stable tumors (HR 0.50 [CI 0.32-0.80] for lowest density tertile and 1.50 [CI 0.87-2.59] for highest density tertile; Pinteraction=0.01). T cell subset analysis showed that DFS benefit for celecoxib use most strongly associated with stromal memory helper T cell density (HR 0.38 [CI 0.26-0.56] for lowest density tertile and 1.26 [CI 0.80-1.97] for highest density tertile; Pinteraction<0.001). Together, these results show that while higher T cell infiltration is associated with improved DFS, lower T cell infiltration is associated with improved DFS for patients treated with celecoxib. This unexpected finding may inform immunomodulatory treatment strategies for CC. Citation Format: Yasutoshi Takashima, Chao Ma, Qian Shi, Andressa Dias Costa, Tyler Twombly, Juha P. Väyrynen, Melissa Zhao, Ardaman Shergill, Pankaj Kumar, Felix Couture, Philip Kuebler, Smitha Krishnamurthi, Benjamin Tan, Eileen M. O'Reilly, Anthony F. Shields, Shuji Ogino, Charles S. Fuchs, Jeffrey A. Meyerhardt, Jonathan A. Nowak. Prognostic and predictive role of T cell infiltration in stage III colon cancer (CC) treated with celecoxib: CALGB/SWOG 80702 [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 5858.
Abstract 5658: Overcoming resistance in mCRPC: drug discovery using PDX models and high-throughput drug screening
Gao, Huanyao , Indulkar, Shreya, Kase, Adam M. , Moore, Cassandra N., Barrett, Michael T. , Weinshilboum, Richard M. , Tan, Winston , Copland, John A. , Wang, Liewei , Marín-Goñi, Irene , Petit, Joachim L. , Kalari, Krishna R. , Weinshilboum, Richard M.

Mayo Clinic

Cancer Research | April 21, 2025 | Volume: 85 | Issue: 8_Supplement_1 | Pages: 5658-5658

10.1158/1538-7445.am2025-5658 Get It

Abstract Background: Second generation androgen receptor signaling inhibitors (ARSIs), such as abiraterone, have demonstrated improved survival in metastatic castration-resistant prostate cancer (mCRPC) patients, however, acquired resistance to these agents often arises. Novel and alternative therapies are needed to combat the ARSI resistant tumor. In the last two decades patient-derived xenograft (PDX) and PDX organoids have become pivotal models in anticancer drug development and biomarker discovery due to their ability to faithfully recapitulate the complex and heterogeneous tumor biology. Methods: We analyzed RNAseq data from mCRPC patients and corresponding PDX models (PROMOTE study, NCT #01953640) and employed L1000 Chem Perturbation down/up signatures database to find candidate drugs to overcome abiraterone resistance by reverse signature search. We then performed proliferation assay using 49 compounds in three PROMOTE-PDX organoid models (2 abiraterone-resistant and 1 abiraterone-sensitive) using our semi high-throughput drug screening platform. Results: Overall, we identified a total of 32 compounds with IC50<10µM in at least one of the models, among which, 5 agents are active in all three models and 5 in at least two of the models. (Table 1). Within active compounds we find selective kinase inhibitors (BRAF, JAK2, AKT, FLT3) and histone deacetylase inhibitors (belinostat and pracinostat). Particularly interesting are two drugs that are only active in the abiraterone resistant setting but not the sensitive PDX. Conclusions: In summary, we leveraged RNAseq data from mCRPC patients and PDX models and performed a high-throughput drug screen in PDX-derived organoid models to identify potential drugs that could overcome abiraterone-resistance in lethal advanced prostate cancer. These data highlight potential drug combinations or subsequent therapeutic strategies for these patients. Citation Format: Irene Marín-Goñi, Huanyao Gao, Joachim L. Petit, Shreya Indulkar, Adam M. Kase, Cassandra N. Moore, Krishna R. Kalari, Michael T. Barrett, Richard Weinshilboum, Winston Tan, John A. Copland, Liewei Wang. Overcoming resistance in mCRPC: drug discovery using PDX models and high-throughput drug screening [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 5658.
GLIM consensus approach to diagnosis of malnutrition: A 5‐year update
Jensen, Gordon L. , Cederholm, Tommy , Correia, María Isabel Toulson Davisson , González, Marı́a Cristina , Fukushima, Ryoji , Pisprasert, Veeradej , Cárdenas, Diana , Carrasco, Fernando , Cruz‐Jentoft, Alfonso J. , Cuerda, Cristina , Evans, David C. , Hasse, Jeanette M. , Hiki, Naoki, Jahit, Mohammad Shukri , Jáquez, Anayanet , Muscaritoli, Maurizio , Ng, Doris Hui Lan , Nyulasi, Ibolya , Pirlich, Matthias , Siltharm, S., Yu, Jianchun , Gossum, A. Van , Winkler, Marion F. , Compher, Charlene , Barazzoni, Rocco , Gautier, Juan B Ochoa , Gonzalez, M Cristina , Blaauw, Renee , Braz, Diana Cardenas , Carrasco, Fernando , Evans, David C , Fuchs-Tarlovsky, Vanessa , Gramlich, Leah , Hasse, Jeanette M , Hiesmayr, Michael , Jager-Wittenaar, Harriët , Jahit, Shukri , Jáquez, Anayanet , Keller, Heather , Malone, Ainsley , Mogensen, Kris M , Mundi, Manpreet S , Muscaritoli, Maurizio , Ng, Doris , Nyulasi, Ibolya , Schneider, Stephane , de van der Schueren, Marian , Singer, Pierre , Tappenden, Kelly A , Yu, Jianchun , Wang, Jaw-Yuan , Winkler, Marion F , Compher, Charlene , Gramlich, Leah , Shi, Han Ping , Kłęk, Stanisław , Malone, Ainsley , Mogensen, Kris M. , Mori, Naoharu , Mundi, Manpreet S. , Steiber, Alison

Mayo Clinic

Journal of Parenteral and Enteral Nutrition | April 14, 2025 | Volume: 49 | Issue: 4 | Pages: 414-427

10.1002/jpen.2756 | PMID 40223699 Get It

Abstract Background The Global Leadership Initiative on Malnutrition (GLIM) introduced an approach for malnutrition diagnosis in 2019 that comprised screening followed by assessment of three phenotypic criteria (weight loss, low body mass index [BMI], and low muscle mass) and two etiologic criteria (reduced food intake/assimilation and inflammation/disease burden). This planned update reconsiders the GLIM framework based on published knowledge and experience over the past 5 years. Methods A working group ( n = 43 members) conducted a literature search spanning 2019–2024 using the keywords “Global Leadership Initiative on Malnutrition or GLIM.” Prior GLIM guidance activities for using the criteria on muscle mass and inflammation were reviewed. Successive rounds of revision and review were used to achieve consensus. Results More than 400 scientific reports were published in peer‐reviewed journals, forming the basis of 10 systematic reviews, some including meta‐analyses of GLIM validity that indicate strong construct and predictive validity. Limitations and future priorities are discussed. Working group findings suggest that assessment of low muscle mass should be guided by experience and available technological resources. Clinical judgment may suffice to evaluate the inflammation/disease burden etiologic criterion. No revisions of the weight loss, low BMI, or reduced food intake/assimilation criteria are suggested. After two rounds of review and revision, the working group secured 100% agreement with the conclusions reported in the 5‐year update. Conclusion Ongoing initiatives target priorities that include malnutrition risk screening procedures, GLIM adaptation to the intensive care setting, assessment in support of the reduced food intake/assimilation criterion, and determination of malnutrition in obesity.
Imaging of the Urachus
Zulfiqar, Maria , Brown, Parker J. , Chughtai, Komal , Navale, Pooja , Tan, Nelly , Yano, Motoyo , Aamir, Asmaa, Tassel, Dane Van , Siegel, Cary , Kawashima, Akira , Van Tassel, Dane , Siegel, Cary Lynn , Kawashima, Akira , Zulfiqar, Maria

Mayo Clinic

RadioGraphics | April 10, 2025 | Volume: 45 | Issue: 5 | Pages: No page available

10.1148/rg.240122 | PMID 40208809 Get It

Frequently overlooked yet clinically significant, the urachus can exhibit a diverse range of pathologic conditions, which can pose a diagnostic challenge at imaging for the radiologist and which require a thorough understanding of urachal embryogenesis.
Precision Prevention through Social Media: Report of Four Cases
López–Campos, Guillermo , Davies, Shauna , Petersen, Carolyn , Petersen, Carolyn , Gabarrón, Elia , Chomutare, Taridzo , Isip-Tan, Iris Thiele

Mayo Clinic

Yearbook of Medical Informatics | April 8, 2025 | Volume: 33 | Issue: 01 | Pages: 052-057

10.1055/s-0044-1800718 | PMID 40199288 Get It

Summary Background: Precision prevention involves using biological, behavioral, socioeconomic, and epidemiological data to improve health for a particular individual or group. With almost 63% of the global population using social media, these platforms show promise to deliver tailored messaging and personalized interventions to individuals. Objectives: To describe the personalization elements and behavior components used in a sample of precision prevention interventions delivered through social media. Methods: To identify examples of cases, a search was done on clinicaltrials.gov, searching for ‘other terms: prevention’ + ‘Intervention/Treatment: social media intervention’ + ‘study results: With results. The selected cases were described, personalization elements reported, and their adopted intervention components were coded according to the Behavior Change Wheel (BCW) framework. Results: A total of four cases employing personalization in their interventions were identified. Three of these cases targeted women's health. The intervention period varied from two to eight months, with participant commitment ranging from active involvement on five out of seven days to monthly participation. The BCW interventions of persuasion and incentivization, were most frequently utilized, while education and coercion were used sparingly in the selected cases. Notably, none of the four cases reported the use of training, restrictions, or modeling. Conclusions: Social media has the potential to serve as a tool for digital phenotyping and contribute to the advancement of precision prevention. Challenges include the social media platform set-up and ensuring all ethical considerations are met.
Beyond the Eyes: The Clinical Spectrum of AFG3L2 Mutations (P6-5.032)
Mutyala, Sarika, Khan, Hina Rmsha Alfia, Tan, Queenie Shu Woon, Mutyala, Sarika, Khan, Hina Rmsha Alfia, Tan, Queenie, Natteru, Prashant

Mayo Clinic

Neurology | April 7, 2025 | Volume: 104 | Issue: 7_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000210562 Get It

Sex Differences in Outcomes of Chimeric Antigen Receptor (CAR) T‐Cell Therapy
Tan, Jia Yi , Kin, Hermon Wong Kha, Ang, Qi Xuan , Ezekwudo, Daniel , Wong, Hermon Kha Kin , Yeo, Yong Hao , Chisti, Mohammad Muhsin , Hilal, Talal

Mayo Clinic

Cancer Medicine | March 27, 2025 | Volume: 14 | Issue: 6 | Pages: No page available

10.1002/cam4.70831 | PMID 40129265 Get It

ABSTRACTBackgroundChimeric Antigen Receptor (CAR) T‐cell therapy has arisen as a revolutionary treatment for hematologic malignancies. Our study aimed to evaluate how sex differences affect outcomes and complications following CAR T‐cell therapy.MethodsUtilizing the Nationwide Readmissions Database (2018–2020), we identified patients and divided them into male and female groups. Hospital outcomes and complications were compared among these two groups after propensity score matching to match groups based on comorbidities, producing two comparable cohorts.ResultsWe analyzed 2928 patients (1832 males, 62.6%, mean age 60.3 ± 13.7 years; 1096 females, 37.4%, mean age 59.1 ± 13.8 years). After propensity score matching (1:1ratio), 1092 males and females were compared. There were no significant sex differences in early mortality (adjusted odd ratios (aOR): 1.04 [95% CI 0.69–1.57]), 30‐day readmissions (aOR: 1.05 [95% CI 0.86–1.30]), or nonhome discharge (aOR: 0.89 [95% CI 0.60–1.31]). Females had higher odds of leukopenia (aOR: 1.26 [95% CI 1.06–1.50]) but lower odds of acute kidney injury (aOR: 0.68 [95% CI 0.52–0.88]).ConclusionsNo sex differences were found in hospital outcomes, including early mortality, 30‐day readmission, and nonhome discharge after CAR T‐cell therapy.
Myeloid targeting antibodies PY159 and PY314 for platinum-resistant ovarian cancer
Yeku, Oladapo , Tan, Winston , Patnaik, Amita , LoRusso, Patricia , Richardson, Debra L. , Naqash, Abdul Rafeh , Lynam, Sarah , Kyriakopoulos, Christos E. , Dowlati, Afshin , Chamberlain, Marc C. , Yeku, Oladapo O , Tan, Winston W., Richardson, Debra L , Kyriakopoulos, Christos E , Naqash, Abdul Rafeh , Barve, Minal , Wang, Judy , Fu, Siqing , Gordon, Michael S. , Hubbard, Joleen M. , Kummar, Shivaani , Winer, Ira Seth

Mayo Clinic

Journal for ImmunoTherapy of Cancer | March 13, 2025 | Volume: 13 | Issue: 3 | Pages: e010959

10.1136/jitc-2024-010959 | PMID 40081941 Get It

Background Novel treatment options are required in patients with platinum-resistant ovarian cancer (PROC). Myeloid-derived suppressor cells promote a hostile tumor microenvironment and are associated with worse clinical outcomes in PROC. We evaluated the safety and preliminary efficacy of PY159, an agonist antibody to Triggering receptor expressed on myeloid cells-1 (TREM1) that reprograms immunosuppressive intratumoral myeloid cells, and PY314, an antagonist antibody to Triggering receptor expressed on myeloid cells-2 (TREM2) that depletes tumor-associated macrophages, as single agents and in combination with pembrolizumab in subjects with PROC. Methods PY159 and PY314 were individually evaluated in patients with PROC. Patients were treated with monotherapy (PY159 3 mg/kg or PY314 10 mg/kg), based on the recommended dose for expansion derived from the phase 1a studies. At the time of first progression, patients could continue study drug and crossover to combination therapy with pembrolizumab (200 mg) every 3 weeks at the discretion of the investigator. Disease assessment by Response Evaluation Criteria in Solid Tumor version 1.1 was performed every 6 weeks. Results 17 patients were enrolled in the PY159 study (median age 67, range 22–77; median prior therapies 6, range 2–18) and 16 patients in PY314 (median age 65.5, range 49–81; median prior therapies 4, range 2–10). 7 patients in PY159 and 8 patients in PY314 crossed over to combination therapy. Safety events included the following: treatment-related adverse events occurred in 15 patients (88.2%) in PY159 and 9 patients (56.3%) in PY314. Infusion-related reactions occurred in 6 patients (35.3%) in PY159 and 3 patients (18.8%) in PY314. Immune-related adverse events occurred in 13 patients (76.5%) in PY159 (arthralgias) and 1 patient (6.3%) in PY314 (diarrhea). Serious adverse events occurred in 6 patients (36.3%) in PY159 (1 related) and 12 patients (75%) in PY314 (all unrelated). The best radiographic response in PY159 was stable disease in 8/16 patients (50%; median 16 weeks, range 9–33), and in PY314, it was stable disease in 8/16 patients (50%; median 12 weeks, range 6–36). Median PFS was 2.76 months and 2.69 months in PY159 and PY314, respectively. There were no responses in the crossover arm. Conclusions Both PY159 and PY314 were well tolerated, with an acceptable safety profile, as both single agents and in combination with pembrolizumab. Both agents warrant further investigation in heavily pretreated PROC.